Journal of the Endocrine Society Journal Article

Diabetes and Hypertension in COVID-19 Patients

September 07, 2020
 

Francisco J Barrera, Skand Shekhar, Rachel Wurth, Pablo J Moreno-Pena, Oscar J Ponce, Michelle Hajdenberg, Neri A Alvarez-Villalobos, Janet E Hall, Ernesto L Schiffrin, Graeme Eisenhofer, Forbes Porter, Juan P Brito, Stefan R Bornstein, Constantine A Stratakis, José Gerardo González-González, René Rodíguez-Gutiérrez, Fady Hannah-Shmouni
Journal of the Endocrine Society, Volume 4, Issue 9, September 2020, bvaa102
https://doi.org/10.1210/jendso/bvaa102

Abstract

Coronavirus disease 2019 (Covid-19) has affected millions of people and may disproportionately affect those with hypertension and diabetes. Because of inadequate methods in published systematic reviews, the prevalence of diabetes and hypertension and associated risks of poor outcomes in Covid-19 patients are unknown. We searched databases from December 1, 2019, to April 6, 2020, and selected observational peer-reviewed studies in English of patients with Covid-19. Independent reviewers extracted data on study participants, interventions, and outcomes and assessed risk of bias, and the certainty of evidence. We included 65 (15 794 participants) observational studies at moderate to high risk of bias. Overall prevalence of diabetes and hypertension was 12% (95% confidence interval [CI], 10–15; n = 12 870; I2: 89%), and 17% (95% CI, 13–22; n = 12 709; I2: 95%), respectively. In severe Covid-19, the prevalence of diabetes and hypertension were 18% (95% CI, 16–20; n = 1099; I2: 0%) and 32% (95% CI, 16–54; n = 1078; I2: 63%), respectively. Unadjusted relative risk for intensive care unit admission and mortality were 1.96 (95% CI, 1.19–3.22; n = 8890; I2: 80%; P = .008) and 2.78 (95% CI, 1.39–5.58; n = 2058; I2: 75%; P = .0004) for diabetics; and 2.95 (95% CI, 2.18–3.99; n = 1737; I2: 0%; P < .001) and 2.39 (95% CI, 1.54–3.73; n = 3107; I2: 66%; P < .001) for hypertensives. Neither diabetes (1.50; 95% CI, 0.90–2.50; n = 1991; I2: 74%; P = .119) nor hypertension (1.48; 95% CI, 0.99–2.23; n = 2023; I2: 69%; P = .058) was associated with severe Covid-19. In conclusion, the risk of intensive care unit admission and mortality for patients with diabetes or hypertension who developed Covid-19 is increased compared with those without these comorbidities.

PROSPERO registration number

CRD42020176582.

Read the article

 

You may also like...

Publishing Benefits

Author Resource Center

We provide our journal authors with a variety of resources for increasing the discoverability and citation of their published work. Use these tools and tips to broaden the impact of your article.
Publishing Benefits

Author Resource Center

We provide our journal authors with a variety of resources for increasing the discoverability and citation of their published work. Use these tools and tips to broaden the impact of your article.

Thematic Issue

Latest Thematic Issue

immuno-endocrinology
Read our special collections of Endocrine Society journal articles, curated by topic, Altmetric Attention Scores, and Featured Article designations.

Read our special collections of Endocrine Society journal articles, curated by topic, Altmetric Attention Scores, and Featured Article designations.

Back to top
Short on time?

We'll come to you...

Get updates on the latest breakthroughs, clinical practice guidelines, and career development opportunities, straight to your inbox

Then take the next step: Set up your free website account and get exclusive access to even more great tools & content!